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Abstract
Background Observational studies suggest an
inequitable prescription of biologics in psoriasis care,
which may be attributed to geographical differences in
treatment access. Sweden regularly ranks high in interna-
tional comparisons of equitable healthcare, and is, in con-
nection with established national registries, an ideal
country to investigate potential inequitable access.
Objective The aim was to determine whether the oppor-
tunity for patients to receive biologics depends on where
they receive care.
Methods Biologic-naı¨ve patients enrolled in the Swedish
National Register for Systemic Treatment of Psoriasis
(PsoReg) from 2008 to 2015 (n = 4168) were included.
The association between the likelihood of initiating a
biologic and the region where patients received care was
analyzed. The strength of the association was adjusted for
patient and clinical characteristics, as well as disease
severity using logistic regression analysis. The proportion
of patients that switched to a biologic (switch rate) and the
probability of switch to a biologic was calculated in 2-year
periods.
Results The national switch rate increased marginally over
time from 9.7 to 11.0%, though the uptake varied across
regions. Adjusted odds ratios for at least one region were
significantly different from the reference region in every
2-year period. During the latest period (2014–2015), the
average patient in the lowest prescribing region was nearly
2.5 times less likely to switch as a similar patient in the
highest prescribing region.
Conclusions Geographical differences in biologics pre-
scription persist after adjusting for patient characteristics
and disease severity. The Swedish example calls for further
improvements in delivering equitable psoriasis care.
Key Points
While the Swedish healthcare system has established
measures against inequitable treatment access,
geographical differences in the prescription of
biologics were present after adjusting for patient
characteristics and disease severity.
Over time, regional differences did not disappear,
nor decrease in magnitude, though the national
switch rate to biologics was stable at approximately
10%.
Evidence of persistent regional differences in access
to biologics motivates similar investigations in other
countries.
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article (doi:10.1007/s40259-016-0209-y) contains supplementary
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Psoriasis is a chronic inflammatory skin disease with a
prevalence rate in adults of 1–5% in the Nordic region
[1–4]. The incidence of psoriasis in Swedish specialist care
between 2007 and 2009 has been estimated at 98 per
100,000 person-years [5]. Patients with moderate-to-severe
psoriasis typically require systemic treatments, which
include conventional systemic agents, small molecule
inhibitors, biological agents (adalimumab, etanercept,
infliximab, ixekizumab, secukinumab, and ustekinumab),
and now even emerging as biosimilars (etanercept and
infliximab). In Sweden, biologics were first available for
psoriasis care in 2004. According to Swedish national
guidelines, biologics are indicated for adult patients with
psoriasis who do not respond to, are intolerant of, or have a
contraindication for conventional systemic treatment.
Before initiating biologics treatment, the condition of
having disease severity scores indicating moderate-to-sev-
ere psoriasis should be fulfilled and consideration should be
given to the location of skin lesions and the presence of
psoriatic arthritis (PsA) [6].
In previous observational studies, some patients with
severe forms of psoriasis were not prescribed biologics,
while others who did not fulfill the criteria for moderate-to-
severe psoriasis received prescription [7, 8]. Aside from
disease severity, a number of factors have been reported to
affect the prescription of biologics. Elderly patients were
observed to be significantly less likely to initiate the
treatment [9]. Males were also observed to be more likely
to be prescribed, though the disparity was attributed to
greater disease severity in males than females [10]. Small
or no difference in prescription was found between types of
healthcare provider [11]. Geographical factors may play a
role as sales of biologics varied internationally in the first
year of use [12]. Within Sweden, sales of biologics per
capita were observed to vary considerably between dif-
ferent geographical entities [13, 14].
Geographical variations in healthcare delivery become a
concerning issue to patients, to payers, and to the medical
community when they cannot be associated with differ-
ences in patient clinical characteristics and disease severity
[15, 16]. At first glance, potential geographical variations
in Sweden may be overlooked. Sweden often ranks high
when compared to other high-income countries with
respect to providing effective and equitable healthcare
[17–21], and goals of equitable healthcare access have been
a governing provision of care for decades in Sweden [22].
Furthermore, prescription medications are free of charge to
patients after accumulating 2200 Swedish Krona (SEK)
[€235; €1 = 9.35 SEK (2016)] in expenses annually and
expenses for medical visits after SEK 1100 (€118) through
tax-financed health insurance covering all citizens, reduc-
ing financial barriers for patients. International rankings
and government initiatives nevertheless typically rely on
readily available general measures relating to overall
healthcare use. Such measures may fail to reveal variations
in subgroups with more well-defined needs. As previous
studies highlight, a pertinent case to investigate is access to
biologics treatment in psoriasis care. By using established
national registries, Sweden is an ideal country to investi-
gate potential inequitable access to biologics treatment
based on regional prescription differences.
The objective of the analyses was to determine whether
the opportunity to receive biologics treatment depends on
where one receives care geographically. To do so, we
investigated potential regional differences in biologics
prescription over time in Sweden by estimating the likeli-
hood of switch to a biologic by region.
2 Materials and Methods
2.1 Study Population
The Swedish National Register for Systemic Treatment of
Psoriasis (PsoReg) was established in 2006 to assess the
long-term safety and effectiveness of systemic psoriasis
treatments in Sweden [23, 24]. PsoReg is a national register
comprising 57 participating dermatology clinics and
departments in hospitals located across Sweden. Health
providers participate voluntarily and enroll people diag-
nosed with psoriasis who are using, or are about to start,
systemic treatment. There has been no change in the
inclusion criteria of the register over time. The study period
was from January 2008 to December 2015.
2.2 Study Design
Included patients were all patients with no prior use of
biologics (biologic-naı¨ve) and could at any time in PsoReg
be switched to biologics or remain on conventional treat-
ment throughout the full study period. A switch was
defined as a first-time prescription of biologics either as an
addition to, or as a replacement of, ongoing conventional
systemics. The study defined treatment with biologics as
any of the biological agents approved for psoriasis in
Sweden during the time of the analysis (adalimumab,
etanercept, efalizumab, infliximab, secukinumab, and
ustekinumab). Efalizumab was withdrawn by the European
Medicines Agency (EMA) in 2009 due to serious side
effects.
To explore time trends, PsoReg data were analyzed in
2-year periods (2008–2009, 2010–2011, 2012–2013, and
2014–2015). Cross-sectional datasets for each period
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comprised biologic-naı¨ve patients who had an observation
during that time. One observation was included per patient;
for patients who never switched to biologics (non-switch-
ers), the last available observation in each 2-year period
was used, while for each patient who switched (switchers),
the last observation before switch was used. Switchers in
the dataset should have had at least one observation before
switch. For both switchers and non-switchers, a registration
of disease severity measured by the Psoriasis Area and
Severity Index (PASI) was required.
2.3 Variables
Regions were defined by the six official healthcare regions
in Sweden: North, South, Stockholm-Gotland, South-East,
Uppsala-O¨rebro, and West. Regions are composed of
geographically neighboring county councils that co-operate
in highly specialized healthcare, among other areas. The
healthcare regions vary in population size between 0.8 and
2 million inhabitants [see Table 3 and Figure 4 in the
electronic supplementary material (ESM)].
Patient characteristics included age and sex. Clinical
characteristics were obesity, defined as body mass index
(BMI) C30, presence of PsA, and clinical types or symp-
toms of psoriasis (nail psoriasis, non-palm pustular, palm
pustular, general pustular, erythroderma, and acrodermati-
tis continua of Hallopeau).
The PASI was used as a measure of disease severity.
The PASI is based on the extent of skin involvement and
ranges from 0 (no disease) to 72 (theoretical maximal
disease) [25]. The patient view of disease impact was
assessed using the Dermatology Life Quality Index
(DLQI). The DLQI score ranges from 0 (quality of life not
impaired) to 30 (quality of life severely impaired).
2.4 Statistical Analysis
The proportion of patients who switched to biologics out of
all patients on conventional systemics, the switch rate, was
first calculated for each time period nationally and
regionally. The difference between the highest and lowest
regional switch rates was calculated. Significant differ-
ences in switch rates between regions in each time period
were tested using the chi-squared test.
Logistic regression models were then used to estimate
adjusted odds ratios (ORs) of switch to a biologic between
healthcare regions in 2-year periods. ORs measure the
likelihood of switch to a biologic in one region compared
with a reference region. Since the Stockholm-Gotland region
as a group had the largest number of patients of all regions,
it was used as the reference region. A separate logistic
regression was performed to estimate the likelihood of
switch between regions for the entire period (2008–2015).
The models were adjusted for risk factors of psoriasis
hypothesized to be associated with the prescription of
biologics and/or stated criteria for biologics use in medical
guidelines. Results were reported as ORs with 95% confi-
dence intervals (CIs). ORs with a CI including one indicate
that the null hypothesis of no association to switch to a
biologic could not be rejected. A Wald test of joint sig-
nificance was conducted to examine if the set of variables
indicating region have significant explanatory power on the
decision to switch to a biologic.
To impute missing DLQI scores, DLQI was regressed
against hypothesized significant predictors of DLQI, such
as PASI, age, and sex. The estimated coefficients from the
regression model were used to predict scores. The model
predicted scores replaced missing DLQI scores. Obesity
was based on registered information on BMI, and people
with missing BMI values were included as not obese.
Data analysis was performed using STATA (StataCorp,
2015; Stata Statistical Software: Release 14; College Sta-
tion, TX, USA; StataCorp LP) and R (R Core Team, 2016;
Version 3.3.0; Vienna, Austria; R Foundation for Statistical
Computing) statistical packages.
3 Results
3.1 Patient and Clinical Characteristics
A total of 4168 unique biologic-naı¨ve patients fulfilled the
inclusion criteria (Fig. 1). When examining registrations in
2-year periods, 1574 biologic-naı¨ve patients had at least
PsoReg
n = 5, 434
Previously treated with biological agent
n = 759
No PASI score recorded
n = 241
No observations before switch recorded
n = 203
No observation during study period
n = 63
Study sample
n = 4, 168
Fig. 1 Flow diagram of patients from the Swedish National Register
for Systemic Treatment of Psoriasis (PsoReg) included in this
analysis. PASI Psoriasis Area and Severity Index
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one registration in PsoReg in 2008–2009, 1936 in
2010–2011, 1959 in 2012–2013, and 1525 in 2014–2015.
Table 1 displays the clinical and demographic character-
istics of biologic-naı¨ve patients in each 2-year period. Over
time, the patient sample increased in the proportion of males
and median BMI, but decreased in median PASI and the
proportion with PsA. Median age and DLQI were constant. In
the latest period (2014–2015), the age of patients ranged from
5 to 94 years old and the median age was 55. Males com-
posed 63% of the cohort, and 21% of patients reported PsA.
In terms of geographical distribution, the Stockholm-
Gotland region held the greatest proportion of patients,
followed by the Western region, over all periods. This
reduced over time as more patients from outside the
Stockholm-Gotland region entered the register. In the latest
period (2014–2015), the Stockholm-Gotland region held
33% of patients, followed by the Western region (25%),
Southern region (18%), South-Eastern region (12%),
Northern region (7%), and lastly Uppsala-O¨rebro (6%).
Out of all 4168 patients, 9% were included in all four
time periods, 17% in three time periods, 26% in two time
periods, and 48% in one period. This corresponds to the
frequency of registrations for each patient: 27% of patients
had one registration, 29% had two to three, while 44% had
four or more. About 6% of study patients had a missing
DLQI value, while 5.5% had a missing BMI value.
3.2 DLQI Imputation
PASI, age, and sex carried statistically significant coeffi-
cients, with sex having the largest effect on predicted
DLQI scores. Higher DLQI was associated with higher
PASI scores and lower age. At most, 8% of DLQI scores
were missing (n = 117) in the 2014–2015 period. Full
regression estimates are given in Table 4 in the ESM.
3.3 Proportion of Patients Switched to Biologics
Approximately 10% of patients on conventional systemics
were switched to biologics during a 2-year period and this
proportion increased over time (Fig. 2). The switch rate
was 9.7% in 2008–2009 and grew to 11.0% in 2014–2015.
A greater proportion of patients were switched in some
regions and a lesser proportion in others. The difference
between the regions with the highest and lowest switch
rates were 10.1 percentage points (pp) in 2008–2009,
9.7 pp in 2010–2011, 18.9 pp in 2012–2013, and 11.2 pp in
2014–2015. Differences in switch rates by region were
significant in each time period (p\ 0.01). Table 2 reports
switch rates for each healthcare region and for Sweden.
3.4 Adjusted Likelihood of Switch
The likelihood of switch to a biologic differed significantly
between healthcare regions in each 2-year period (see
Fig. 3). The Western, Northern, and Southern regions were
less likely to switch patients compared to the reference
region, Stockholm-Gotland, in the early years, particularly
in 2008–2009. All regions except the Western region had
similar switching patterns in 2010–2011, though in the
following period (2012–2013), each region deviated from
the Stockholm-Gotland region. Patients from the South-
Eastern and Uppsala-O¨rebro regions were more than twice
as likely to be switched compared to similar patients from




systemic agents at their last
observed contact and of those
patients who switched to a
biologic agent at the observation
closest in time before the switch
to a biologic occurred
2008–2009 2010–2011 2012–2013 2014–2015
Number of patients 1574 1936 1959 1525
Male, n (%) 935 (59) 1,162 (60) 1,179 (60) 965 (63)
Age (years), median (IQR) 55 (43–64) 55 (43–65) 55 (43–66) 55 (43–66)
BMI, median (IQR) 26.9 (24.2–30.5) 27.1 (24.3–30.5) 27.1 (24.2–30.8) 27.1 (24.2–31.2)
PASI, median (IQR) 4.0 (2.0–8.0) 3.8 (2.0–7.2) 3.5 (1.8–6.8) 3.5 (1.8–6.9)
DLQI, median (IQR) 3.0 (1.0–7.0) 3.0 (1.0–7.0) 3.0 (1.0-7.0) 3.0 (1.0–7.0)
Psoriatic arthritis, n (%) 438 (28) 507 (26) 454 (23) 319 (21)
Healthcare region, n (%)
Stockholm-Gotland 653 (42) 741 (38) 654 (33) 502 (33)
West 344 (22) 382 (20) 461 (24) 374 (25)
South 189 (12) 303 (16) 363 (19) 275 (18)
North 244 (16) 293 (15) 229 (12) 105 (7)
South-East 72 (5) 125 (6) 140 (7) 190 (12)
Uppsala-O¨rebro 72 (5) 92 (5) 112 (6) 88 (6)
Notes: Percentage of patients in healthcare regions may not total 100 due to rounding
BMI body mass index, IQR interquartile range, PASI Psoriasis Area and Severity Index, DLQI Dermatology
Life Quality Index
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the Stockholm-Gotland region. At the same time, patients
from the Western and Southern regions were less than half
as likely to be switched. In the latest period (2014–2015),
the Western, Southern, and Uppsala-O¨rebro regions con-
tinued to have significantly different likelihood of switch.
Indicator variables on healthcare regions were jointly sig-
nificant as predictors of switch to a biologic in all periods
(Wald test p\ 0.01).
Other covariates were associated with the likelihood of
switch to a biologic. As expected, the adjusted ORs of
PASI were greater than one and statistically significant
[OR (95% CI) above one] for all periods. The adjusted ORs
for PsA were greater than one and statistically significant
for 2008–2009 and 2010–2011. While the estimate of
adjusted ORs for PASI increased in magnitude over time,
the corresponding estimate for PsA became insignificant.
DLQI did not carry significant adjusted ORs for any period.
The adjusted ORs for the age variable were less than one
and statistically significant [OR (95% CI) below one] in all
periods.
For the entire registration period (2008–2015), the
adjusted ORs for the Western (adjusted OR = 0.41, 95%
CI 0.32–0.53), Northern (adjusted OR = 0.55, 95% CI
0.41–0.74), and Southern (adjusted OR = 0.70, 95% CI
0.54–0.89) regions were less than one and statistically

























Fig. 2 The proportion of patients with moderate-to-severe psoriasis
switched to biologics over time (switch rate), for Sweden and for the
regions with the highest and lowest switch rates
Table 2 The proportion of
patients who switched to
biologics out of all biologic-
naı¨ve patients on conventional
systemics (switch rate) for each
healthcare region and for
Sweden
2008–2009 2010–2011 2012–2013 2014–2015
Stockholm-Gotland 90/653 (13.78) 80/741 (10.80) 75/654 (11.47) 47/502 (9.36)
West 13/344 (3.78) 17/382 (4.45) 31/461 (6.72) 26/374 (6.95)
Uppsala-O¨rebro 10/72 (13.89) 13/92 (14.13) 25/112 (22.32) 16/88 (18.18)
South 13/189 (6.88) 31/303 (10.23) 17/363 (4.68) 45/275 (16.36)
South-East 7/72 (9.72) 21/125 (16.80) 33/140 (23.57) 29/190 (15.26)
North 19/244 (7.79) 29/293 (9.90) 16/229 (6.99) 5/105 (9.76)
Sweden 152/1574 (9.66) 191/1936 (9.87) 197/1959 (10.06) 168/1525 (11.02)
Using Chi-squared tests, statistically significant differences in switch rate were found between regions in




















































Fig. 3 Adjusted odds ratios
(ORs) from the logistic
regression of switch to a
biologic against healthcare
regions whilst adjusting for
disease severity, patient and
clinical characteristics, and





insignificant difference in ORs
to the reference region,
Stockholm-Gotland
(OR = 1.00)
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estimates for 2-year periods and the full registration period
are given in the ESM.
4 Discussion
While the Swedish healthcare system has several measures
against inequitable treatment access, our data showed that
there are significant and persistent regional differences in
biologics prescription in the case of psoriasis, also after
adjusting for patient characteristics and standard measures
of disease severity. This should motivate further investi-
gations into reasons for the observed variation of access to
biologics in Sweden and in other countries with goals of
equitable healthcare access.
Switch to a biologic was more likely in some years than
other years within a given region, though at the same time,
the national switch rate was stable at approximately 10%.
Over time, regional differences did not disappear, nor
decrease in magnitude. A decade after the introduction of
biologics in Sweden, these differences persist, suggesting
that treatment options for patients with psoriasis depend on
where care is received.
The main strength of this register-based study is that
PsoReg allows for the possibility to adjust for disease
impact in terms of PASI and DLQI. Clinical data are
generally not available in administrative registries. Data
used from PsoReg also encompass a long time period of
10 years, including time before patients were on biologics
(if prescribed). Furthermore, PsoReg has nationwide cov-
erage, with an estimated 65% of all Swedish patients with
psoriasis on biologics enrolled. With these advantages,
treatment patterns were described as they happened in real-
world clinical practice, which enhances the external
validity of the results.
Nonetheless, register-based research has inherent limi-
tations, some of which are shared by other research
designs. Confounding due to unobserved patient and
physician preferences, for instance, may influence treat-
ment adherence, patient quality of life, and likewise, the
decision to prescribe biologics. Another limitation is the
unavailability of information to ascertain data coverage and
representativeness. As disease severity of patients in
PsoReg is not registered elsewhere, there is insufficient
data to externally validate how the register has tracked the
actual rate of switches to biologics in psoriasis. Never-
theless, the research questions addressed in this study do
not require full coverage. Our interest was to find patients
in the register with similar characteristics and disease status
but treated in different regions, and to see if they are
equally likely to be prescribed biologics. The registration
of patients using systemic treatments, conventional and/or
biologics, in PsoReg is not likely to systemically differ by
region given that PsoReg has a national platform and its
inclusion criteria apply equally to all regions. A regression
for the entire registration period was conducted to check
whether the use of PsoReg over time may have affected
results. As in our main analysis, notable regional differ-
ences were found over the entire period.
A few empirical studies have investigated medical
practice variation within dermatology, and particularly in
psoriasis care [26–28]. In rheumatology, a Swedish study
based on the administrative register of prescribed drugs
explored differences in the sale of tumor necrosis factor
(TNF) inhibitors, a subgroup of biologics, between county
councils and healthcare regions in 2000 and 2009 [13]. The
per capita sales of TNF inhibitors were about twice as high
in the region with the highest sales compared to the region
with the lowest sales. In that study, the Western region of
Sweden had the lowest TNF inhibitor sales per capita
(approximately €14 per capita) and the lowest proportion
of people with rheumatoid arthritis using TNF inhibitors
(11%). Even when adjusting for covariates, as conducted in
our study, a lower likelihood of switch to a biologic in the
Western region of Sweden was observed. The same pattern
of regional variation appears for both psoriasis and
rheumatoid arthritis. When examining trends in recent
years in this study, the Western region was still less likely
to prescribe, though the gap has reduced. Interestingly, the
reduction corresponds to a change in the treatment guide-
lines of the region implemented from 2014 onwards, where
biologics could be initiated at an earlier stage than before
[29, 30].
From an international perspective, the regional variation
in the uptake of TNF inhibitors has been explored in
rheumatology [31, 32]. Whereas significant differences
were found in types of patients initiating TNF inhibitors in
Canadian provinces, no significant differences were
observed in UK healthcare regions.
The likelihood of switch to a biologic was not found to
correlate with socioeconomic differences between the
regions (see Table 3 in the ESM). It seems unlikely that the
variation observed stems from regional differences in
socio-economic status or differences in the composition of
healthcare tax base. Other supply-side differences includ-
ing characteristics of decision-making structures and
capacity constraints have been identified as important for
healthcare provision [33].
Yet, regional variation can be expected when novel
therapies, such as biologics in the early 2000s, are intro-
duced, as some regions and types of providers may adapt to
new medical technology faster than others [34, 35]. The
Stockholm-Gotland region could thus be considered as
early adopters of biologics since patients in the region were
more likely to switch early on. Part of the supply-side
source of variation would be expected to diminish over
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time as biologics become fully implemented in psoriasis
care. Nevertheless, more than a decade later, regional dif-
ferences in biologics use persist, suggesting that patients
may have inequitable access to biologics depending on
where they live. Not only does it makes psoriasis care less
patient-centered [36], it also creates a situation that is at
odds with the aim of providing equal access to care. It is
therefore important to further review evidence and expe-
rience from national registries such as PsoReg to investi-
gate prescription trends in psoriasis. The effect of new
biosimilars on future prescription trends, for instance,
could be investigated.
The Swedish healthcare system may be viewed as a
testing case for assessing equitable access to biologics.
While several measures are in place to combat disparities
in healthcare delivery, geographical differences were per-
sistent. Further improvements could be made to promote
equitable access in psoriasis care.
5 Conclusions
Geographical differences in biologics prescription persist
after adjusting for patient characteristics and disease
severity, suggesting that treatment options for patients with
psoriasis depend on where care was received. This calls for
further improvement towards delivering equitable psoriasis
care.
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